Cannabis Science Inc. (OTCMKTS:CBIS) Completes Testing And Validation Of Proprietary Vacuum Distillation Process

Cannabis Science Inc. (OTCMKTS:CBIS) has announced that Cannabis Science Europe GmbH, its wholly-owned subsidiary, has managed to successful complete the testing as well as validations of its short-time vacuum distillation process. The distillation is for enhancement of CBD extracts containing high Cannabidiolic Acid levels that is subsequently converted into CBD powder and water purified soluble CBDA.

Cannabis Science’s proprietary distillation process

In the process of completing the testing the company has managed to quickly and affordably expand its present production capacity to more than 1,000 kilograms of CBD extract and purified CBDA per month. Cannabis Science is expecting to expand its production ability so as to meet its clinical, wholesale and private label customer needs.

The proprietary short-time vacuum distillation process that the company is using determines the appropriate temperature, pressure and the accurate time to minimise loss of CBDA as well as the other essential cannabinoid acids. In the testing of the process the company used CBD extract that contained less than 0.2% THC levels and 7.3% CBD and in the first step of purification cannabis Science managed to produce Purified extract containing 0.6% THC and 26% CBD. From the purified extract the company managed to produce CBD powder that contains 3.5% CBD, 3.5% CBDA and THC levels below 0.02%.

Bypassing oxidation process produces quality CBDA and CBD extract

Usually cannabinoids will become unstable during the oxidation process when mixed with water but with the proprietary distillation process the company will manage to bypass the oxidation process. As a result they will provide an effective product that keeps the nutritional CBD and CBDA levels for over a long time compared to the water-diluted CBD products.

CEO and Co-founder of Cannabis Science Raymond Dabney stated that the company is preparing itself for its Global Development Initiatives. He added the distillation process is another significant milestone for the company as it aggressively reaches into the global market with cost effective purified water soluble CBDA powders ad CBD extracts. Dabney said that the company plans to increase its supplies for clinical research develop the company as well as produce private label products for clients.

By Steven Russell

Steve covers business and investing in emerging medical marijuana markets. Steve graduated from the university of New Orleans with a degree in Broadcast Journalism. Steve has published several articles in professional journals and magazines. His experience gives readers an inside look at the intersection of his specialties, business and medical marijuana.

Leave a Reply

Your email address will not be published. Required fields are marked *

Pin It on Pinterest